Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Risankizumab

Catalog No. T76778Cas No. 1612838-76-2
Alias SKYRIZI, Risankizumab rzaa, BI-655066, ABBV 066

Risankizumab (BI 655066) is a humanized IgG monoclonal antibody (Kd <10 pM) targeting the IL-23 p19 subunit. It inhibits IL-17 production induced by human IL-23 in mouse splenocytes with an IC50 value of 2 pM. Risankizumab is used for the prevention and treatment of immune and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis.

Risankizumab

Risankizumab

Purity: 98.3% (SEC-HPLC)
Catalog No. T76778Alias SKYRIZI, Risankizumab rzaa, BI-655066, ABBV 066Cas No. 1612838-76-2
Risankizumab (BI 655066) is a humanized IgG monoclonal antibody (Kd <10 pM) targeting the IL-23 p19 subunit. It inhibits IL-17 production induced by human IL-23 in mouse splenocytes with an IC50 value of 2 pM. Risankizumab is used for the prevention and treatment of immune and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis.
Pack SizePriceAvailabilityQuantity
1 mg$243In Stock
5 mg$793In Stock
10 mg$1,230In Stock
Bulk & Custom
Add to Cart
Questions
View More
Select Batch
Concentration:3.93 mg/mL
Purity:98.3% (SEC-HPLC)
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
Risankizumab (BI 655066) is a humanized IgG monoclonal antibody (Kd <10 pM) targeting the IL-23 p19 subunit. It inhibits IL-17 production induced by human IL-23 in mouse splenocytes with an IC50 value of 2 pM. Risankizumab is used for the prevention and treatment of immune and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis.
Targets&IC50
IL-17:17 pM (cynomolgus), IL-17:2 pM (human), IL-23:10pM (kd,human), IL-23:10pM (kd,cynomolgus)
In vitro
With Kds <10 pM, Risankizumab (BI 655066) exhibits high affinity for human and cynomolgus IL23[3]. Risankizumab (BI 655066) inhibits endogenous (THP-1 cell generated) human IL23-induced and recombinant cynomolgus IL23-induced IL17 production with IC50s of 2 pM and 17 pM, respectively[2].
In vivo
In mice, Risankizumab (BI 655066) inhibits IL23-induced ear swelling and cytokine production following a single intraperitoneal (i.p.) dosage of 1 mg/kg[2].
AliasSKYRIZI, Risankizumab rzaa, BI-655066, ABBV 066
Chemical Properties
Molecular Weight145.85 kDa
Cas No.1612838-76-2
Storage & Solubility Information
Storagestore at low temperature | store at -20°C | Shipping with blue ice.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: buy Risankizumab | purchase Risankizumab | Risankizumab cost | order Risankizumab | Risankizumab chemical structure | Risankizumab in vivo | Risankizumab in vitro | Risankizumab molecular weight